How Vast Government Aid and Imaginative Enforcement Could Mean FCA Liability for a Growing Breadth of Industries
Client Alert | less than 1 min read | 06.10.21
Over the past few years, both the government and False Claims Act relators (whistleblowers) have targeted more types of defendants than they have ever previously. Against this backdrop, Congress passed two of the largest relief bills in modern history and thus even more companies find themselves involved with the federal government in a new way or for the first time This article examines the government’s enforcement of FCA against such new or non-traditional defendants and provides key takeaways.
Contacts
Insights
Client Alert | 4 min read | 04.08.26
Cosmetics Under the Microscope: FDA’s Expanding Regulatory Reach Under MoCRA
The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) marked the most significant expansion of FDA’s authority over cosmetics in 80 years — and the agency is putting that authority to work. From the launch of a new adverse event reporting tool to forthcoming rules on fragrance allergens and good manufacturing practices (GMP), FDA is reshaping the regulatory landscape for manufacturers, packers, and distributors of cosmetic and personal care products.
Client Alert | 3 min read | 04.07.26
Answering the Top Seven Questions About Pending Section 301 Deadlines
Client Alert | 3 min read | 04.07.26
EU Pharma Package: Fiscal Imports in the Supply Chain Compromise Proposal
Client Alert | 5 min read | 04.07.26
